Literature DB >> 12829616

Engineering the response to vascular injury: divergent effects of deregulated E2F1 expression on vascular smooth muscle cells and endothelial cells result in endothelial recovery and inhibition of neointimal growth.

David A Goukassian1, Raj Kishore, Kevin Krasinski, Christine Dolan, Corinne Luedemann, Young-sup Yoon, Marianne Kearney, Allison Hanley, Hong Ma, Takayuki Asahara, Jeffrey M Isner, Douglas W Losordo.   

Abstract

Tumor necrosis factor-alpha (TNF-alpha) is expressed locally in the vessel wall after angioplasty and induces growth arrest and apoptosis in endothelial cells (ECs), thereby delaying reendothelialization. Prior studies have shown that direct antagonism of TNF-alpha, using a systemically administered soluble receptor, can enhance endothelial recovery and reduce neointimal thickening. These studies have also shown that downregulation of the transcription factor E2F1 was a key mechanism of TNF's effect on ECs. We now show that Ad-E2F1 overexpression at sites of balloon injury accelerates functional endothelial recovery, consistent with the prior in vitro findings. Moreover these studies also reveal divergent effects of TNF-alpha and overexpression of E2F1 on ECs versus VSMCs. TNF-alpha exposure of VSMCs had no affect on proliferation or apoptosis, in contrast to the effect seen in ECs. In Ad-E2F1-transduced VSMCs, however, TNF-alpha-induced marked apoptosis in contrast to the survival effect seen in ECs. Finally, these studies suggest that differential activation of NF-kappaB may play a key role in mediating these opposing effects. Nuclear translocation and transcriptional activity of NF-kappaB was markedly attenuated in Ad-E2F1-transduced VSMCs, whereas it remained active in similarly treated ECs when the cells were exposed to TNF-alpha. These studies reveal that overexpression of Ad-E2F1 primes VSMCs to TNF-alpha-induced apoptosis. Furthermore, E2F1 potentiates VSMC death by blocking antiapoptotic signaling pathway through inhibition of NF-kappaB activation. The divergent responses of VSMCs and ECs to E2F1 overexpression provide unique therapeutic possibilities: simultaneously targeting the cell cycle of two different cell types, within same tissue microenvironment resulting in opposite and biologically complimentary effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829616     DOI: 10.1161/01.RES.0000082980.94211.3A

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  10 in total

1.  Notch signaling regulates endothelial progenitor cell activity during recovery from arterial injury in hypercholesterolemic mice.

Authors:  Masaaki Ii; Kyosuke Takeshita; Kayoko Ibusuki; Corinne Luedemann; Andrea Wecker; Elizabeth Eaton; Tina Thorne; Takayuki Asahara; James K Liao; Douglas W Losordo
Journal:  Circulation       Date:  2010-02-22       Impact factor: 29.690

2.  The cytoskeletal protein ezrin regulates EC proliferation and angiogenesis via TNF-alpha-induced transcriptional repression of cyclin A.

Authors:  Raj Kishore; Gangjian Qin; Corinne Luedemann; Evelyn Bord; Allison Hanley; Marcy Silver; Mary Gavin; Young-sup Yoon; David Goukassian; David Goukassain; Douglas W Losordo
Journal:  J Clin Invest       Date:  2005-06-16       Impact factor: 14.808

3.  TNF-α response of vascular endothelial and vascular smooth muscle cells involve differential utilization of ASK1 kinase and p73.

Authors:  S Rastogi; W Rizwani; B Joshi; S Kunigal; S P Chellappan
Journal:  Cell Death Differ       Date:  2011-07-08       Impact factor: 15.828

4.  E2F1 promotes angiogenesis through the VEGF-C/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-B.

Authors:  David Engelmann; Deborah Mayoli-Nüssle; Christian Mayrhofer; Katharina Fürst; Vijay Alla; Anja Stoll; Alf Spitschak; Kerstin Abshagen; Brigitte Vollmar; Sophia Ran; Brigitte M Pützer
Journal:  J Mol Cell Biol       Date:  2013-09-06       Impact factor: 6.216

5.  Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF.

Authors:  Gangjian Qin; Raj Kishore; Christine M Dolan; Marcy Silver; Andrea Wecker; Corinne N Luedemann; Tina Thorne; Allison Hanley; Cynthia Curry; Lindsay Heyd; Deepika Dinesh; Marianne Kearney; Fabio Martelli; Toshinori Murayama; David A Goukassian; Yan Zhu; Douglas W Losordo
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-11       Impact factor: 11.205

6.  Sam68 impedes the recovery of arterial injury by augmenting inflammatory response.

Authors:  Shuling Han; Shiyue Xu; Junlan Zhou; Aijun Qiao; Chan Boriboun; Wenxia Ma; Huadong Li; Dauren Biyashev; Liu Yang; Eric Zhang; Qinghua Liu; Shayi Jiang; Ting C Zhao; Prasanna Krishnamurthy; Chunxiang Zhang; Stéphane Richard; Hongyu Qiu; Jianyi Zhang; Gangjian Qin
Journal:  J Mol Cell Cardiol       Date:  2019-10-19       Impact factor: 5.000

Review 7.  Intimal hyperplasia in murine models.

Authors:  David Y Hui
Journal:  Curr Drug Targets       Date:  2008-03       Impact factor: 3.465

8.  Functional disruption of alpha4 integrin mobilizes bone marrow-derived endothelial progenitors and augments ischemic neovascularization.

Authors:  Gangjian Qin; Masaaki Ii; Marcy Silver; Andrea Wecker; Evelyn Bord; Hong Ma; Mary Gavin; David A Goukassian; Young-sup Yoon; Thalia Papayannopoulou; Takayuki Asahara; Marianne Kearney; Tina Thorne; Cynthia Curry; Liz Eaton; Lindsay Heyd; Deepika Dinesh; Raj Kishore; Yan Zhu; Douglas W Losordo
Journal:  J Exp Med       Date:  2006-01-09       Impact factor: 14.307

9.  Effects of LDL Receptor Modulation on Lymphatic Function.

Authors:  Andreea Milasan; François Dallaire; Gaétan Mayer; Catherine Martel
Journal:  Sci Rep       Date:  2016-06-09       Impact factor: 4.379

10.  Dimethylfumarate attenuates restenosis after acute vascular injury by cell-specific and Nrf2-dependent mechanisms.

Authors:  Chang Joo Oh; Sungmi Park; Joon-Young Kim; Han-Jong Kim; Nam Ho Jeoung; Young-Keun Choi; Younghoon Go; Keun-Gyu Park; In-Kyu Lee
Journal:  Redox Biol       Date:  2014-06-24       Impact factor: 11.799

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.